Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Formela sold 26,587 shares of Korro Bio stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $15.08, for a total transaction of $400,931.96. Following the transaction, the director directly owned 128,089 shares in the company, valued at approximately $1,931,582.12. This trade represents a 17.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jean Francois Formela also recently made the following trade(s):
- On Thursday, November 12th, Jean Formela sold 40,045 shares of Korro Bio stock. The stock was sold at an average price of $14.30, for a total transaction of $572,643.50.
- On Wednesday, August 26th, Jean Formela sold 300 shares of Korro Bio stock. The stock was sold at an average price of $13.96, for a total value of $4,188.00.
- On Wednesday, August 19th, Jean Formela sold 28,468 shares of Korro Bio stock. The stock was sold at an average price of $14.00, for a total value of $398,552.00.
Korro Bio Stock Performance
KRRO opened at $13.61 on Monday. The company has a fifty day simple moving average of $11.86 and a 200 day simple moving average of $12.16. The firm has a market cap of $186.87 million, a price-to-earnings ratio of -1.50 and a beta of 3.23. Korro Bio, Inc. has a twelve month low of $5.20 and a twelve month high of $17.35.
Korro Bio (NASDAQ:KRRO – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.16. On average, analysts forecast that Korro Bio, Inc. will post -4.45 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have weighed in on KRRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a report on Friday, October 2nd. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Korro Bio in a research note on Tuesday, October 6th. Wall Street Zen upgraded shares of Korro Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, Jefferies Financial Group set a $15.00 price target on shares of Korro Bio in a research report on Tuesday, October 6th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Korro Bio has a consensus rating of “Buy” and an average price target of $17.29.
View Our Latest Report on KRRO
Institutional Investors Weigh In On Korro Bio
Several institutional investors and hedge funds have recently made changes to their positions in KRRO. China Universal Asset Management Co. Ltd. acquired a new position in Korro Bio in the third quarter worth $54,000. North Star Investment Management Corp. increased its stake in Korro Bio by 1,044.4% during the third quarter. North Star Investment Management Corp. now owns 20,600 shares of the company’s stock valued at $204,000 after purchasing an additional 18,800 shares during the last quarter. Deutsche Bank AG bought a new stake in Korro Bio during the second quarter valued at $210,000. Hsbc Holdings PLC acquired a new stake in shares of Korro Bio during the second quarter worth $233,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Korro Bio by 15.2% during the first quarter. Bank of New York Mellon Corp now owns 21,730 shares of the company’s stock worth $246,000 after purchasing an additional 2,875 shares during the period. 13.18% of the stock is owned by institutional investors and hedge funds.
About Korro Bio
Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.
Recommended Stories
- Five stocks we like better than Korro Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
